Dexmedetomidine — or “Dex” — has become one of the most intriguing and versatile drugs in the anesthesia world. In this episode of Anesthesia Alchemy with hosts Lynn Macksey, MSN, CRNA and Garry Brydges, PhD, DNP, MBA, CRNA, ACNP-BC, FAAN dive deep into the pharmacology, clinical application, and emerging research surrounding this alpha-2 agonist. Here’s some of what we discuss in this episode: 🧠 CNS receptor action and sedative pathways 💉 IV, buccal, spinal, and local delivery methods 🫁 Organ protection and anti-inflammatory effects 🛏️ Potential future use as a sleep aid 🧬 Promising research on cancer immunity and stress modulation Visit us online: https://beyondthemaskpodcast.com/ The 1099 CRNA Institute: https://aana.com/1099 Get the CE Certificate here (and directly submit to the NBCRNA): https://beyondthemaskpodcast.com/wp-content/uploads/2020/04/Beyond-the-Mask-CE-Cert-FILLABLE.pdf Help us grow by leaving a review: https://podcasts.apple.com/us/podcast/beyond-the-mask-innovation-opportunities-for-crnas/id1440309246

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related